Chromodomain-helicase-DNA Binding Protein 5, 7 and Pronecrotic Mixed Lineage Kinase Domain-like Protein Serve As Potential Prognostic Biomarkers in Patients with Resected Pancreatic Adenocarcinomas

Overview

Journal World J Gastrointest Oncol

Publisher Baishideng Publishing Group

Date 2016 Apr 21

PMID 27096031

Citations 9

Authors

Crystal S Seldon

Lauren E Colbert

William A Hall

Sarah B Fisher

David S Yu

Jerome C Landry

Affiliations

Soon will be listed here.

Abstract

Pancreatic cancer is one of the deadliest cancers with a very poor prognosis. Recently, there has been a significant increase in research directed towards identifying potential biomarkers that can be used to diagnose and provide prognostic information for pancreatic cancer. These markers can be used clinically to optimize and personalize therapy for individual patients. In this review, we focused on 3 biomarkers involved in the DNA damage response pathway and the necroptosis pathway: Chromodomain-helicase-DNA binding protein 5, chromodomain-helicase-DNA binding protein 7, and mixed lineage kinase domain-like protein. The aim of this article is to review present literature provided for these biomarkers and current studies in which their effectiveness as prognostic biomarkers are analyzed in order to determine their future use as biomarkers in clinical medicine. Based on the data presented, these biomarkers warrant further investigation, and should be validated in future studies.

Citing Articles

Characterizing the prognostic and therapeutic value of necroptosis in sarcoma based on necroptosis subtypes.

Ma Y, Yuan Q, He S, Mao X, Zheng S, Chen C Front Genet. 2022; 13:980209.

PMID: 36238158 PMC: 9552825. DOI: 10.3389/fgene.2022.980209.

Pan-cancer analysis of a novel indicator of necroptosis with its application in human cancer.

Liu A, Li Y, Shen L, Li N, Shen L, Li Z Aging (Albany NY). 2022; 14(18):7587-7616.

PMID: 36170029 PMC: 9550240. DOI: 10.18632/aging.204307.

Regulated cell death (RCD) in cancer: key pathways and targeted therapies.

Peng F, Liao M, Qin R, Zhu S, Peng C, Fu L Signal Transduct Target Ther. 2022; 7(1):286.

PMID: 35963853 PMC: 9376115. DOI: 10.1038/s41392-022-01110-y.

MLKL deficiency in BrafPten melanoma model results in a modest delay of nevi development and reduced lymph node dissemination in male mice.

Martens S, Takahashi N, Blancke G, Vandamme N, Verschuere H, Divert T Cell Death Dis. 2022; 13(4):347.

PMID: 35422482 PMC: 9010476. DOI: 10.1038/s41419-022-04819-4.

MLKL in cancer: more than a necroptosis regulator.

Martens S, Bridelance J, Roelandt R, Vandenabeele P, Takahashi N Cell Death Differ. 2021; 28(6):1757-1772.

PMID: 33953348 PMC: 8184805. DOI: 10.1038/s41418-021-00785-0.

References

Karhu R, Mahlamaki E, Kallioniemi A . Pancreatic adenocarcinoma -- genetic portrait from chromosomes to microarrays. Genes Chromosomes Cancer. 2006; 45(8):721-30. DOI: 10.1002/gcc.20337. View

Jones S, Wang T, Shih I, Mao T, Nakayama K, Roden R . Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 2010; 330(6001):228-31. PMC: 3076894. DOI: 10.1126/science.1196333. View

Berger M, Lawrence M, Demichelis F, Drier Y, Cibulskis K, Sivachenko A . The genomic complexity of primary human prostate cancer. Nature. 2011; 470(7333):214-20. PMC: 3075885. DOI: 10.1038/nature09744. View

Engelen E, Akinci U, Bryne J, Hou J, Gontan C, Moen M . Sox2 cooperates with Chd7 to regulate genes that are mutated in human syndromes. Nat Genet. 2011; 43(6):607-11. DOI: 10.1038/ng.825. View

Wu X, Zhu Z, Li W, Fu X, Su D, Fu L . Chromodomain helicase DNA binding protein 5 plays a tumor suppressor role in human breast cancer. Breast Cancer Res. 2012; 14(3):R73. PMC: 3446335. DOI: 10.1186/bcr3182. View

Sun L, Wang H, Wang Z, He S, Chen S, Liao D . Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell. 2012; 148(1-2):213-27. DOI: 10.1016/j.cell.2011.11.031. View

Malkoski S, Wang X . Two sides of the story? Smad4 loss in pancreatic cancer versus head-and-neck cancer. FEBS Lett. 2012; 586(14):1984-92. PMC: 3285395. DOI: 10.1016/j.febslet.2012.01.054. View

Blackford A, Serrano O, Wolfgang C, Parmigiani G, Jones S, Zhang X . SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res. 2009; 15(14):4674-9. PMC: 2819274. DOI: 10.1158/1078-0432.CCR-09-0227. View

Li M, Zhao H, Zhang X, Wood L, Anders R, Choti M . Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet. 2011; 43(9):828-9. PMC: 3163746. DOI: 10.1038/ng.903. View

10.

Zhao R, Yan Q, Lv J, Huang H, Zheng W, Zhang B . CHD5, a tumor suppressor that is epigenetically silenced in lung cancer. Lung Cancer. 2011; 76(3):324-31. DOI: 10.1016/j.lungcan.2011.11.019. View

11.

Yadav D, Lowenfels A . The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology. 2013; 144(6):1252-61. PMC: 3662544. DOI: 10.1053/j.gastro.2013.01.068. View

12.

Tempero M, Uchida E, Takasaki H, Burnett D, Steplewski Z, Pour P . Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res. 1987; 47(20):5501-3. View

13.

Forones N, Tanaka M . CEA and CA 19-9 as prognostic indexes in colorectal cancer. Hepatogastroenterology. 1999; 46(26):905-8. View

14.

Tenev T, Bianchi K, Darding M, Broemer M, Langlais C, Wallberg F . The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol Cell. 2011; 43(3):432-48. DOI: 10.1016/j.molcel.2011.06.006. View

15.

Loy T, Sharp S, Andershock C, Craig S . Distribution of CA 19-9 in adenocarcinomas and transitional cell carcinomas. An immunohistochemical study of 527 cases. Am J Clin Pathol. 1993; 99(6):726-8. DOI: 10.1093/ajcp/99.6.726. View

16.

Bagchi A, Papazoglu C, Wu Y, Capurso D, Brodt M, Francis D . CHD5 is a tumor suppressor at human 1p36. Cell. 2007; 128(3):459-75. DOI: 10.1016/j.cell.2006.11.052. View

17.

Iacobuzio-Donahue C, Fu B, Yachida S, Luo M, Abe H, Henderson C . DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009; 27(11):1806-13. PMC: 2668706. DOI: 10.1200/JCO.2008.17.7188. View

18.

He L, Peng K, Liu Y, Xiong J, Zhu F . Low expression of mixed lineage kinase domain-like protein is associated with poor prognosis in ovarian cancer patients. Onco Targets Ther. 2013; 6:1539-43. PMC: 3817086. DOI: 10.2147/OTT.S52805. View

19.

Hall W, Petrova A, Colbert L, Hardy C, Fisher S, Saka B . Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy for resected pancreatic cancer. Oncogene. 2013; 33(47):5450-6. DOI: 10.1038/onc.2013.488. View

20.

Paul S, Kuo A, Schalch T, Vogel H, Joshua-Tor L, McCombie W . Chd5 requires PHD-mediated histone 3 binding for tumor suppression. Cell Rep. 2013; 3(1):92-102. PMC: 3575599. DOI: 10.1016/j.celrep.2012.12.009. View